logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
Cancer Chemotherapy and Pharmacology cover

Cancer Chemotherapy and Pharmacology

IF2.3
Papers216
Citations9031
Journal Papers 203
Publication Date
delete
A phase 1, open-label study evaluating the pharmacokinetics, safety, and tolerability of vepdegestrant in Chinese patients with ER+/HER2- advanced breast cancer
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-08-13
delete0
PREAI
deleteBinghe Xu; Jin Yang; Pin Zhang; Wenna Wang; Liang Zhang; Xiao’ai Zhao; Fei Guan; Naihan Chen; Huadong Zhao; Cong Fei
deleteShare
deleteSave
Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-08-12
delete0
PREAI
deleteJianli Zhou; Daruka Mahadevan; Jay Parekh; Marc Chamberlain; Kishor Bhatia; Reginald Ewesuedo
deleteShare
deleteSave
Physiologically based pharmacokinetic modeling to predict human pharmacokinetics of a novel mithramycin analog for Ewing sarcoma
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-08-12
delete0
deleteOAAI
deleteKumar Kulldeep Niloy; Jamie Horn; Nazmul Hasan Bhuiyan; Suhas S. Bhosale; Khaled A. Shaaban; Thomas E. Prisinzano; Jon S. Thorson; Jurgen Rohr; Markos Leggas
deleteShare
deleteSave
Associations of body composition with neoadjuvant chemotherapy response, toxicity, and prognosis in breast cancer: a scoping review
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-08-12
delete0
deleteOAAI
deleteSamantha Ligertwood; Femi E. Ayeni; Andrew Parsonson; Senarath Edirimanne
deleteShare
deleteSave
Pharmacological inhibition of store-operated calcium entry enhances sorafenib-induced antitumor effects in Huh7 hepatocellular carcinoma cells
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-08-12
delete0
PREAI
deleteBeste Yurdacan Yasar; Elmasnur Yilmaz; Yasemin Erac
deleteShare
deleteSave
Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-08-03
delete0
deleteOAAI
deleteKarolijn W. M. Groot Beumer; E. M. J. Durlinger; S. W. J. Zielhuis; R. ter Heine; A. D. R. Huitema; J. J. M. A. Hendrikx
deleteShare
deleteSave
Development of a simplified population pharmacokinetic–pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-28
delete0
deleteOAAI
deleteYoshinori Makino; Takanori Ogawa; Reiko Makihara–Ando; Naomi Sakiyama; Masahito Yamazaki; Chizuru Naito; Hiroki Takayama; Genji Ueda; Shunsuke Kohyama; Maki Todo; Yasuhiro Kuwata; Masataka Hirasaki; Tetsuya Hamaguchi
deleteShare
deleteSave
Red blood cell partitioning and the interpretation of palbociclib plasma concentrations - a letter to the editor
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-20
delete0
PREAI
deleteJulie Sowa; Sophia Chabane; Fanny Bret; Samuel Huguet; Manon Launay
deleteShare
deleteSave
Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-20
delete0
PREAI
deleteYoshitomo Yanagimoto; Kazuyoshi Yamamoto; Kei Yamamoto; Yasunori Masuike; Yuki Ushimaru; Takeshi Omori; Daisuke Sakai; Toshihiro Kudo; Norihiro Matsuura; Takahito Sugase; Takashi Kanemura; Ryota Mori; Masahiko Kubo; Yasunari Fukuda; Masatoshi Kitakaze; Hisateru Komatsu; Masaaki Miyo; Toshinori Sueda; Junichi Nishimura; Yoshinori Kagawa; Kunihito Goto; Shogo Kobayashi; Hiroshi Miyata
deleteShare
deleteSave
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-18
delete0
PREAI
deleteClémence Marin; Anthéa Deschamps; Quentin Gerbault; Clémence Toullec; Florian Clatot; Maureen Bernadach; Jérôme Fayette; Amaury Daste; Philippe Ceruse; Mickael Burgy; Cédric Champetier; Cyril Abdeddaim; Esma Saada-Bouzid; Xavier Tchiknavorian; Sylvie Zanetta; Pascal Auquier; Joseph Ciccolini; Sébastien Salas
deleteShare
deleteSave
Design characteristics of mass balance studies conducted for protein kinase inhibitors
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-13
delete0
deleteOAAI
deleteBenthe Riechelman; Ramon Bolks; Thijs H. Oude Munnink; Jesse J. Swen; Frank G. A. Jansman; Frank Klont
deleteShare
deleteSave
Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-13
delete0
deleteOAAI
deleteVanessa Armenio Scontre; Marcos Tadashi Kakitani Toyoshima; Maria Del Pilar Estevez-Diz
deleteShare
deleteSave
The value of target-site physiologically-based pharmacokinetics for high-affinity small molecules: a mechanistic foundation for precision dosing in oncology and hematology
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-13
delete0
deleteOAAI
deleteSuzanne van der Gaag; Daniela E. Oprea-Lager; André N. Vis; Harry Hendrikse; Imke H. Bartelink
deleteShare
deleteSave
Anti-PD-1 single-chain variable fragments in cancer immunotherapy: from molecular engineering to clinical translation
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-09
delete0
PREAI
deleteZahraa AlKhafaje; H. Malathi; Aniruddh Dash; J. Precilla Selvakumari; Gurjant Singh; Aashna Sinha; Muath Suliman; Aseel Smerat
deleteShare
deleteSave
Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-07
delete0
deleteOAAI
deleteMaiko Abumiya; Ko Abe; Atsushi Watanabe; Naoto Takahashi
deleteShare
deleteSave
Successful oral desensitization to temozolomide in a patient with immediate hypersensitivity reaction
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-07
delete0
PREAI
deleteEce Şahinoğlu; Muhittin Akarsu; Selma Yalçın; Dilşad Mungan; Zeynep Celebi Sozener
deleteShare
deleteSave
Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-06
delete0
deleteOAAI
deleteJason Charamis; Nikolaos Katzilakis; Eftichia Stiakaki; Ioannis Kyriakidis
deleteShare
deleteSave
The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-06
delete0
deleteOAAI
deleteA. C. Kanhailal; M. J. J. Lucassen; T. Schutte; W. Zwart; A. D. R. Huitema; N. Steeghs
deleteShare
deleteSave
Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-02
delete0
PREAI
deleteMichiaki Nakajo; Tomonobu Uchino; Kazuhiro Asada; Ichiro Hatta; Ryuji Yumoto; Mayuko Okada; Yuna Iwano; Yui Nabekura; Yasunori Miyazaki; Kanami Ikeda; Tasuku Yokoyama; Yoshiyuki Kagawa; Daiki Tsuji
deleteShare
deleteSave
CDK4/6 inhibitor–statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review
deleteCancer Chemotherapy and Pharmacology
IF2.3
delete2026-07-01
delete0
deleteOAAI
deleteRafael Batista João; Leonardo Ribeiro Soares; Paulo César Ragazzo; Ruffo Freitas-Junior
deleteShare
deleteSave